Correct usage, dosage and dosage adjustment standards of eflornithine (IWILFIN)

Eflornithine (IWILFIN) is an oral anti-tumor drug mainly used to treat specific types of tumors. The drug exerts a therapeutic effect by inhibiting the activity of targeted enzymes and blocking tumor cell proliferation. Correct use of this drug is crucial to ensure efficacy and safety. The dose is generally calculated based on the patient's body surface area (BSA) and is administered orally in two divided doses per day.

Depending on the body surface area, the recommended dosage is as follows:

Body surface area>1.5 m²: 768mg (4 tablets), twice a day;

Body surface area0.75–1.5 m²: 576mg (3 tablets), twice daily;

Body surface area0.5–＜0.75 m²: 384mg (2 tablets), twice a day;

Body surface area0.25–＜0.5 m²: 192mg (1 tablet), twice daily.

This dosing regimen ensures appropriate drug exposure for patients of all sizes to maximize efficacy.

During the treatment process, the dose should be adjusted according to the patient's hematological indicators, liver and kidney function and clinical tolerance . If serious side effects occur, such as neutropenia, elevated liver enzymes, or obvious gastrointestinal reactions, temporary discontinuation of the drug, delay in administration, or dose reduction may be considered. At the same time, regular monitoring of blood routine, liver and kidney function and electrolytes will help to adjust the dose safely and reasonably.

Eflornithine should be used under the guidance of a doctor in strict accordance with the dosage calculated according to the body surface area and should not be increased or decreased by oneself. During treatment, combined use with other highly toxic drugs should be avoided to reduce the risk of complications. Patients and their families should pay attention to adverse reactions and seek medical treatment promptly, while maintaining regular medication and review to ensure efficacy and medication safety.

Reference materials:https://www.drugs.com/